Verrica director granted 16,000 stock options
Verrica Pharmaceuticals director Gavin Corcoran received a grant of stock options covering 16,000 shares of common stock at an exercise price of $6.04 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Verrica Pharmaceuticals director Gavin Corcoran received a grant of stock options covering 16,000 shares of common stock at an exercise price of $6.04 per share. These options vest in 12 equal monthly installments beginning on July 5, 2026, and will be fully vested by the next annual stockholder meeting, subject to his continued service. Following this compensation award, Corcoran holds 16,000 stock options directly.
Insider Trade Summary
Grant/Award: 16,000 shares
Grant/Award
1 txn
Insider
Corcoran Gavin
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 16,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 16,000 contracts (Direct)
Footnotes (1)
- F1. The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date.
Key Figures
Option grant size: 16,000 options
Exercise price: $6.04 per share
Expiration date: June 4, 2036
+4 more
7 metrics
Option grant size
16,000 options
Stock Option (right to buy) covering common stock
Exercise price
$6.04 per share
Conversion or exercise price of stock options
Expiration date
June 4, 2036
Option expiration for 16,000-share grant
Shares underlying options
16,000 shares
Underlying Verrica common stock for the option grant
Post-grant option holdings
16,000 options
Total derivative holdings following the transaction
Vesting start date
July 5, 2026
Monthly vesting begins for the option grant
Vesting schedule
12 monthly installments
Equal monthly vesting, fully vested by next annual meeting
Key Terms
Stock Option (right to buy), Common Stock, exercise price, vest and become exercisable, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: 6.0400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments"
annual meeting of stockholders financial
"fully vested on the date of the next annual meeting of stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Verrica Pharmaceuticals (VRCA) director Gavin Corcoran report in this Form 4?
Gavin Corcoran reported receiving a stock option grant for 16,000 shares of Verrica Pharmaceuticals common stock. The options were granted as compensation, carry a $6.04 exercise price, and are held directly, increasing his derivative-based exposure to the company.
What are the key terms of Gavin Corcoran’s new Verrica (VRCA) stock options?
The new stock options cover 16,000 shares of Verrica common stock at a $6.04 exercise price and expire on June 4, 2036. They represent a long-dated incentive aligning the director’s potential upside with future company performance over a multi-year period.
How do Gavin Corcoran’s Verrica (VRCA) options vest over time?
The 16,000 Verrica options vest in 12 equal monthly installments starting July 5, 2026. They will in any event be fully vested by the date of the next annual meeting of stockholders, assuming Corcoran continues to serve as a director through each vesting date.
What is Gavin Corcoran’s Verrica (VRCA) option position after this Form 4?
After the reported grant, Corcoran holds 16,000 stock options directly, each exercisable for one share of Verrica common stock. The filing does not show additional derivative positions, so this award defines his visible option-based stake as of the transaction date.
When do Gavin Corcoran’s Verrica (VRCA) stock options expire?
The 16,000 Verrica stock options granted to Gavin Corcoran expire on June 4, 2036. This long expiration period provides an extended timeframe during which he may choose to exercise the options, depending on future company performance and Verrica’s share price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates